Correlation Between Coya Therapeutics, and Regenxbio
Can any of the company-specific risk be diversified away by investing in both Coya Therapeutics, and Regenxbio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Coya Therapeutics, and Regenxbio into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Coya Therapeutics, Common and Regenxbio, you can compare the effects of market volatilities on Coya Therapeutics, and Regenxbio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Coya Therapeutics, with a short position of Regenxbio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Coya Therapeutics, and Regenxbio.
Diversification Opportunities for Coya Therapeutics, and Regenxbio
-0.36 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Coya and Regenxbio is -0.36. Overlapping area represents the amount of risk that can be diversified away by holding Coya Therapeutics, Common and Regenxbio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Regenxbio and Coya Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Coya Therapeutics, Common are associated (or correlated) with Regenxbio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Regenxbio has no effect on the direction of Coya Therapeutics, i.e., Coya Therapeutics, and Regenxbio go up and down completely randomly.
Pair Corralation between Coya Therapeutics, and Regenxbio
Given the investment horizon of 90 days Coya Therapeutics, Common is expected to generate 1.25 times more return on investment than Regenxbio. However, Coya Therapeutics, is 1.25 times more volatile than Regenxbio. It trades about 0.03 of its potential returns per unit of risk. Regenxbio is currently generating about -0.05 per unit of risk. If you would invest 601.00 in Coya Therapeutics, Common on September 6, 2024 and sell it today you would earn a total of 8.00 from holding Coya Therapeutics, Common or generate 1.33% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Insignificant |
Accuracy | 98.44% |
Values | Daily Returns |
Coya Therapeutics, Common vs. Regenxbio
Performance |
Timeline |
Coya Therapeutics, Common |
Regenxbio |
Coya Therapeutics, and Regenxbio Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Coya Therapeutics, and Regenxbio
The main advantage of trading using opposite Coya Therapeutics, and Regenxbio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Coya Therapeutics, position performs unexpectedly, Regenxbio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regenxbio will offset losses from the drop in Regenxbio's long position.Coya Therapeutics, vs. Cue Biopharma | Coya Therapeutics, vs. Lantern Pharma | Coya Therapeutics, vs. Fennec Pharmaceuticals | Coya Therapeutics, vs. Eliem Therapeutics |
Regenxbio vs. Day One Biopharmaceuticals | Regenxbio vs. Replimune Group | Regenxbio vs. Mirum Pharmaceuticals | Regenxbio vs. Rocket Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Complementary Tools
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Transaction History View history of all your transactions and understand their impact on performance |